Skip to main content
JIANERKANG MEDICAL CO., LTD. logo

JIANERKANG MEDICAL CO., LTD. — Investor Relations & Filings

Ticker · 603205 ISIN · CNE100006PP8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 123 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603205

About JIANERKANG MEDICAL CO., LTD.

https://en.chinajek.com/

Jianerkang Medical Co., Ltd. specializes in the research, development, and large-scale manufacturing of medical consumables and surgical dressings. The company's product portfolio includes a wide range of medical gauze, non-woven products, wound care dressings, bandages, and personal protective equipment such as surgical masks and gowns. Utilizing advanced production technologies and automated facilities, the firm maintains rigorous quality control standards, holding international certifications including ISO, CE, and FDA registrations. Jianerkang serves a global clientele, supplying healthcare institutions and distributors across international markets. Its operations focus on providing high-quality, sterile, and non-sterile medical supplies designed for clinical safety and patient care efficiency.

Recent filings

Filing Released Lang Actions
健尔康医疗科技股份有限公司关于公司财务总监辞职的公告
Regulatory Filings
2026-06-02 Chinese
上海市广发律师事务所关于健尔康医疗科技股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a legal opinion letter by a law firm on the convening, attendance, voting procedures and detailed vote results of the company’s 2025 Annual Shareholders’ Meeting. It includes the official voting tallies (approve/oppose/abstain) for each AGM proposal. This corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Chinese
健尔康医疗科技股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “2025年年度股东会决议公告” and details the attendance, agenda items, and specific vote counts and percentages for each resolution at the company’s 2025 Annual General Meeting. It is clearly an official announcement of shareholder voting results rather than the report itself, fitting the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Chinese
健尔康医疗科技股份有限公司关于开展远期结售汇业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding the commencement of forward foreign exchange settlement and sales business. It details the transaction purpose, amount, funding source, transaction method, term, risk analysis, risk control measures, and accounting treatment. It also includes the board's approval and the sponsor's verification opinion. The document is a formal announcement of a specific financing-related activity (foreign exchange forward contracts) and does not contain financial statements or quarterly/yearly financial results. It is not a full financial report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to foreign exchange risk management.
2025-12-29 Chinese
健尔康医疗科技股份有限公司关于2026年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2026. It includes information about the board and audit committee approvals, transaction amounts, related parties, pricing policies, and the impact on the company. The document is an announcement of expected related party transactions, which is a regulatory disclosure typically required by stock exchanges for transparency. It is not a full financial report, audit report, or management discussion, nor is it a voting result or a meeting presentation. The document length is about 3,242 characters, which is relatively short and focused on a specific regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-29 Chinese
中信建投证券股份有限公司关于健尔康医疗科技股份有限公司2026年度日常关联交易预计的核查意见
Regulatory Filings Classification · 90% confidence The document is a detailed sponsor’s verification opinion (核查意见) regarding the company’s expected 2026 routine related‐party transactions, prepared under exchange listing rules. It is not an annual or interim report, not a proxy or AGM material, but rather a regulatory compliance filing (sponsor attestation). It contains substantive attestations and approvals by board committees and independent directors, fulfilling exchange regulatory requirements. It does not constitute an Annual Report or other specific category, so it falls under the general regulatory filings category.
2025-12-29 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.